SCHEMBL20139451

SCHEMBL20139451

CCc1ccc(Br)cc1C(O)c1ccc2c(c1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HSP90AA1 P07900 1/20 0.42
GAA P10253 1/20 0.42
HSD17B3 P37058 4/20 0.35
CARM1 Q86X55 2/20 0.34
ACACB O00763 1/20 0.34
HTT P42858 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
MEN1 O00255 1/20 0.32
TDP1 Q9NUW8 3/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MAPT P10636 2/20 0.31
MELK Q14680 1/20 0.31
SRD5A1 P18405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139400 0.81 KMT2A (0.42) KMT2AALDH1A1HSP90AA1GAAHSD17B3
SCHEMBL20139416 0.78 ALDH1A1 (0.39) KMT2AALDH1A1HSP90AA1GAAHSD17B3
SCHEMBL20140360 0.78
SCHEMBL20140072 0.78 KMT2A (0.40) KMT2AALDH1A1HSP90AA1GAATDP1
SCHEMBL20139705 0.78 ALDH1A1 (0.40) KMT2AALDH1A1HSP90AA1GAAHSD17B3
SCHEMBL20139430 0.74 EPHX2 (0.33) KMT2AALDH1A1HSP90AA1GAAACACB
SCHEMBL20139452 0.72 ALDH1A1 (0.40) KMT2AALDH1A1HSP90AA1GAAHTT
SCHEMBL20140032 0.72 HTR2A (0.41) KMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20139699 0.72 HPGD (0.44) KMT2AALDH1A1HSP90AA1GAAHTT
SCHEMBL12291535 0.71 ADRB2 (0.38) KMT2AALDH1A1GAAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 KMT2A 1219/4885ALDH1A1 2392/4885HSP90AA1 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.